Clinical Trials Logo

Malignant Solid Tumour clinical trials

View clinical trials related to Malignant Solid Tumour.

Filter by:

NCT ID: NCT01554371 Completed - Neuropathy Clinical Trials

Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

Start date: March 27, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety of eribulin (Halaven™) and cyclophosphamide (Cytoxan®) given together at different doses. This study will look at what effects, good and/or bad, that these drugs have on solid tumors. Eribulin is a drug that has been approved by the FDA for breast cancer that has spread to other parts of the body. Cyclophosphamide has been approved for different types of cancers (including breast cancer). However, the combination of eribulin and cyclophosphamide is considered experimental; that means this combination has not been approved by the FDA. The funding for this study is provided by Eisai Inc., the maker of eribulin.

NCT ID: NCT01435096 Completed - Clinical trials for Malignant Solid Tumour

BN80927 in Patients With Advanced Malignant Solid Tumors

Start date: November 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study was to determine the maximum tolerated dose and the recommended dose of BN80927 in patients with advanced malignant solid tumors.

NCT ID: NCT01376505 Completed - Breast Cancer Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Start date: June 21, 2011
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.

NCT ID: NCT01343498 Completed - Clinical trials for Malignant Solid Tumour

Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors

Start date: April 2011
Phase: Phase 1
Study type: Interventional

This is a dose escalation trial to evaluate twice daily dosing of the sachet formulation of BEZ235. This trial will find the maximum tolerated dose (MTD) of the sachet formulation given twice daily, as well as evaluate pharmacokinetics (PK) and pharmacodynamics (PD) of the twice daily dosing. Patients will initially be given once daily dosing to determine the PK and PD of the single daily dose. On Day 9, they will begin twice daily dosing, with half of the single daily dose divided twice daily, and PK and PD of the twice daily dose will be determined.

NCT ID: NCT01337505 Completed - Clinical trials for Malignant Solid Tumour

Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

Start date: April 2011
Phase: Phase 1
Study type: Interventional

This is a phase 1b open-label study evaluating the preliminary safety and maximum tolerated dose of a new formulation of INNO-206 administered at doses of 230 mg/m2, 350 mg/m2 and 450 mg/m2 (165, 260, 325 mg/m2 doxorubicin equivalents, respectively) through intravenous infusion on Day 1 every 21 days for up to 6 cycles.

NCT ID: NCT01325558 Completed - Clinical trials for Locally Advanced Malignant Neoplasm

A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

Start date: May 2011
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-836 in combination with standard of care gemcitabine in participants who have locally advanced or metastatic solid tumors. The purpose of this study is to determine the maximum tolerated dose (MTD), and to assess the safety and pharmacokinetic profile of ALT-836 given with gemcitabine. The clinical benefit, progression-free survival and overall survival of study participants will also be assessed.

NCT ID: NCT01184807 Completed - Clinical trials for Malignant Solid Tumour

Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors

Start date: December 2009
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized, dose-escalation trial in patients with advanced solid tumors. The trial comprises 2 stages: a dose escalation stage at 8 dose levels of 2, 5, 10, 20, 40, 60, 80, and 100 mg/day,and possibly additional intermediate doses, to determine the MTD and recommended dose, and a subsequent 2 parts of expansion stage to investigate the safety profile and antitumor effect of OPB-51602 at the recommended dose.

NCT ID: NCT01023737 Completed - Clinical trials for Malignant Solid Tumour

Hydroxychloroquine + Vorinostat in Advanced Solid Tumors

Start date: November 2009
Phase: Phase 1
Study type: Interventional

This study is an open label non randomized study of hydroxychloroquine (HCQ) with histone deacetylase (HDAC) inhibitor Vorinostat in patients with advanced solid tumors to determine the maximum tolerated dose (MTD) and to evaluate the safety and antitumor activity of this drug combination.

NCT ID: NCT00969410 Completed - Liver Metastases Clinical Trials

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases

Start date: August 2009
Phase: Phase 1
Study type: Interventional

A pharmacodynamic study to evaluate the effect of AV-299 on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases. To evaluate safety and tolerability of AV-299 administered IV in subjects with advanced solid tumors who have liver metastases.

NCT ID: NCT00635791 Completed - Clinical trials for Renal Cell Carcinoma

Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

Start date: March 2008
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of giving vorinostat and sorafenib tosylate together in treating patients with kidney or non-small cell lung cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may stop the growth of solid tumors by blocking blood flow to the tumor. Giving vorinostat together with sorafenib tosylate may kill more tumor cells.